Jefferies has increased its price target for Murphy Oil to $35 from $33, despite the stock trading above this target at $41.74. The upgrade follows significant oil discoveries offshore Vietnam and Côte d’Ivoire, along with production starting at key projects like Chinook #8 and Vietnam's Lac Da Vang field. These developments are expected to boost Murphy Oil's future cash flow and financial performance. The company’s recent capital budget increases reflect strong investment in exploration, signaling positive momentum for investors in the energy sector.
Murphy Oil's stock price stands at $41.74, above Jefferies' raised target of $35. For readers following the energy sector, here is Pluang's market snapshot as of Oct 19, 2026 19:15 WIB: out of 79 priced US energy stocks, 25 rose and 47 fell. Notable movers include PBF Energy Inc. at USD 82.88 with a 1-day change of -1.94%, Enphase Energy Inc. at USD 31.16 up 1.76%, and Denison Mines Corp at USD 2.32 up 1.75%.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
